November 6, 2020

Dear Colleagues and friends,

I am happy to learn that the Society of Nuclear Medicine, India (SNMI) is organizing their 52nd Annual Conference, SNMICON-2020 in a hybrid mode. These are difficult times for all of us; however, the wheels of science must continue to turn at an even rapid pace as the whole world looks up to the physician scientists around the globe to bring an end to the ongoing crisis. In keeping with the current requirements and the ‘new normal’, virtual conferences are an appropriate solution to ensure that scientific dialogue is continued unabated. I would like to congratulate the Society of Nuclear Medicine, India and the organizers of SNMICON-2020 for bringing together the scientists and researchers from different parts of the world to a common hybrid platform. Understanding the necessity of the hour, we must continue to evolve and make the best use of the available resources for the progress of Medicine.

This year’s conference theme of ‘Nuclear Medicine: Re-defining Precision Oncology’ is a perfect reminder of the diagnostic and therapeutic capabilities of Nuclear Medicine. The field of Nuclear Medicine theranostics is already on the leading edge of personalized precision medicine. We must strive even harder to ensure that we deliver the most personalized, evidence-based, precision medicine to our patients for the most optimal outcomes. I am pleased to note that theranostics has picked up quite well in India and several centres have been engaged in PRRT, PSMA based RLT and the newer alpha-therapies. We need to work towards establishing standardized dosimetry techniques in order to optimize therapeutic results in patients with minimal adverse effects. It is my pleasure to speak to the conference attendees and share my experience in nuclear medicine and precision medicine.

I look forward to seeing you at the congress (virtually!).

Sincerely,

Richard L. Wahl, MD